Boehringer Ingelheim International GmbH

Five-Year Study Shows Aflibercept Treat-and-Extend Regimen Maintains Vision in Neovascular AMD Patients

2 months ago

• A multicenter Japanese study demonstrates that aflibercept using a treat-and-extend regimen maintained baseline visual acuity and significantly reduced central macular thickness in neovascular AMD patients over five years. • Researchers identified smaller greatest linear dimension (GLD) as the only independent risk factor associated with better vision outcomes after five years of treatment (p=0.0024). • The study revealed patients required fewer injections after the first year, though 33% of discontinued cases experienced recurrence, with higher recurrence rates in those who had received more total injections.

Circulating DNA/RNA Market Set to Triple to $16.4 Billion by 2032, Driven by Patent Innovations

2 months ago

• The global circulating DNA/RNA market is projected to grow from $5.32 billion in 2023 to $16.4 billion by 2032, advancing at a CAGR of 13.29% according to a new patent landscape report. • Key industry players Nantomics, Genentech, and Novartis are leading innovation in the sector, with the United States dominating patent activity with over 600 patents, followed by Europe and Asia. • The oncology segment leads patent filings, with technological advancements in non-invasive diagnostics and personalized medicine driving market expansion and creating new opportunities in genomic medicine.

Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost

2 months ago

• Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility. • Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet. • The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.

Efficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder

4 months ago

A phase 2 trial evaluated the efficacy and safety of BI 1358894, a novel TRPC4/5 inhibitor, in treating Borderline Personality Disorder (BPD). Despite showing safety and tolerability, the trial did not meet its primary efficacy endpoint, with no significant differences observed between treatment groups and placebo. The study highlights the challenges of high placebo responses in BPD trials and the need for novel treatment approaches.